Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01537159 · ClinicalTrials.gov registry record
MRI Assessment of Leukemia Response to Therapy
A clinical trial, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- 23
- Enrollment target
NCT01537159: Completed study, sponsored by OHSU Knight Cancer Institute.
NCT01537159 is a clinical trial that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01537159 has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate if a type of magnetic resonance imaging (MRI) scan of the bone marrow before the start of standard chemotherapy can predict complete remission of leukemia patients after the therapy. This type of MRI scan, called dynamic contrast-enhanced MRI (DCE-MRI), measures bone marrow blood flow. For those patients who do not achieve complete remission status after initial therapy and will be treated with additional therapy, the investigators are also interested in determining if the second MRI exam before the additional therapy can predict complete remission. If successfully tested, the MRI exam may be used in the future to help with early identification of patients who are unlikely to respond to standard chemotherapy. This will allow for a personalized therapeutic plan to be developed for these patients at an early stage and prevent them from being exposed to toxic and ineffective therapies.
Primary Outcome
To explore if Shutter-Speed Model (SSM) dynamic contrast-enhanced MRI (DCE-MRI)of the bone marrow (BM) can predict complete remission (CR) in newly diagnosed or relapsed acute myelogenous leukemia (AML)patients.
Interventions
- DEVICE 3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2012-05 |
| Est. Completion | 2018-12-31 |
What the finished NCT01537159 record still lists
NCT01537159 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which 3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system is the first listed.
NCT01537159 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01537159 about?
NCT01537159 is a clinical study titled "MRI Assessment of Leukemia Response to Therapy". The purpose of this study is to investigate if a type of magnetic resonance imaging (MRI) scan of the bone marrow before the start of standard chemotherapy can predict complete remission of leukemia patients after the therapy. This type of MRI scan, called dynamic contrast-enhanced MRI (DCE-MRI), me...
What is the current status of trial NCT01537159?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2012-05. Estimated completion is 2018-12-31.
What interventions are being tested in trial NCT01537159?
The interventions under investigation include: 3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system (DEVICE).
Who is sponsoring clinical trial NCT01537159?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia